IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
+8.51%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$1.13B
AUM Growth
+$1.13B
(+33%)
Cap. Flow
+$321M
Cap. Flow
% of AUM
28.43%
Top 10 Holdings %
Top 10 Hldgs %
39.2%
Holding
99
New
35
Increased
28
Reduced
13
Closed
17
Top Buys
| 1 |
Centene
CNC
|
$30.3M |
| 2 |
Cardinal Health
CAH
|
$29.6M |
| 3 |
Vera Therapeutics
VERA
|
$27.5M |
| 4 |
CVS Health
CVS
|
$22.4M |
| 5 |
Neurocrine Biosciences
NBIX
|
$21.8M |
Top Sells
| 1 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$35M |
| 2 |
Novartis
NVS
|
$23M |
| 3 |
Tenet Healthcare
THC
|
$16.4M |
| 4 |
Arcellx
ACLX
|
$13.4M |
| 5 |
Medtronic
MDT
|
$12M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Insmed
INSM
$28.8B
| $107M | 9.12% | 1,550,000 +100,000 | +7% | +$6.9M |
|
|
2
Tenet Healthcare
THC
$16.3B
| $50.5M | 4.3% | 400,000 -130,000 | -25% | -$16.4M |
|
3
Boston Scientific
BSX
$156B
| $49.1M | 4.19% | 550,000 | – | – |
|
|
4
Vera Therapeutics
VERA
$1.38B
| $48.6M | 4.15% | 1,150,000 +650,000 | +130% | +$27.5M |
|
5
Cytokinetics
CYTK
$4.23B
| $47M | 4.01% | 1,000,000 +250,000 | +33% | +$11.8M |
|
|
6
Centene
CNC
$14.3B
| $30.3M | 2.58% | +500,000 | New | +$30.3M |
|
|
7
Cardinal Health
CAH
$35.5B
| $29.6M | 2.52% | +250,000 | New | +$29.6M |
|
8
Eli Lilly
LLY
$657B
| $29.3M | 2.5% | 38,000 +28,000 | +280% | +$21.6M |
|
9
Encompass Health
EHC
$12.3B
| $27.7M | 2.36% | 300,000 +25,000 | +9% | +$2.31M |
|
10
Revolution Medicines
RVMD
$7.1B
| $24.1M | 2.05% | 550,000 +200,000 | +57% | +$8.75M |
|
|
BPMC
11
DELISTED
Blueprint Medicines
BPMC
| $24M | 2.04% | 275,000 -15,000 | -5% | -$1.31M |
|
|
12
CVS Health
CVS
$92.8B
| $22.4M | 1.91% | +500,000 | New | +$22.4M |
|
|
13
Neurocrine Biosciences
NBIX
$13.8B
| $21.8M | 1.86% | +160,000 | New | +$21.8M |
|
14
Intuitive Surgical
ISRG
$170B
| $20.9M | 1.78% | +40,000 | New | +$20.9M |
|
15
McKesson
MCK
$85.4B
| $19.9M | 1.7% | +35,000 | New | +$19.9M |
|
16
Merck
MRK
$210B
| $19.9M | 1.7% | 200,000 | – | – |
|
17
Bristol-Myers Squibb
BMY
$96B
| $19.8M | 1.69% | 350,000 +175,000 | +100% | +$9.9M |
|
18
Quest Diagnostics
DGX
$20.3B
| $19.6M | 1.67% | 130,000 +10,000 | +8% | +$1.51M |
|
19
uniQure
QURE
$896M
| $19.4M | 1.66% | 1,100,000 +700,000 | +175% | +$12.4M |
|
20
Tarsus Pharmaceuticals
TARS
$2.47B
| $19.4M | 1.65% | 350,000 -25,000 | -7% | -$1.38M |
|
21
Inspire Medical Systems
INSP
$2.77B
| $18.5M | 1.58% | 100,000 -60,000 | -38% | -$11.1M |
|
22
Gilead Sciences
GILD
$140B
| $18.5M | 1.57% | +200,000 | New | +$18.5M |
|
|
NARI
23
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $17.9M | 1.52% | 350,000 -50,000 | -13% | -$2.55M |
|
24
Scholar Rock
SRRK
$3.14B
| $16.2M | 1.38% | 375,000 +100,000 | +36% | +$4.32M |
|
25
BrightSpring Health Services
BTSG
$4.2B
| $16.2M | 1.38% | 950,000 +450,000 | +90% | +$7.66M |
|